首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 核酸藥物

市場調查報告書

商品編碼

1272658

多□治療市場：現狀分析與預測（2022-2030）

Peptide Therapeutics Market: Current Analysis and Forecast (2022-2030)

出版日期: 2023年04月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 156 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於新藥開發的製藥投資增加，預計□治療市場在預測期內將以 9% 的複合年增長率增長。例如，2021 年 9 月，Nimble Therapeutics 與 Incyte 合作發現了新型□療法。此外，2020 年 7 月，IRBM 啟動了與默克公司的研究合作，以開發先進的□療法。預計此類投資將推動未來幾年的市場增長

根據藥物類型，市場分為品牌藥和仿製藥。 2021年品牌產品將佔據較大市場份額，主要是由於藥企加大研發投入、產品上市以及高處方率。

按給藥途徑，藥物分為母體劑、粘膜劑、口服劑和透皮劑。父類別將在 2021 年主導市場。高采用率、快速給藥和易於使用等幾個因素是全球市場採用率不斷提高的主要原因。目前，大多數□療法是通過親本途徑遞送的，這也將在未來幾年推動市場增長。

按照應用，市場分為癌症、新陳代謝、心血管疾病、呼吸系統、血液疾病、抗感染、皮膚科、中樞神經系統等。由於□療法的高特異性和靶向性，預計腫瘤學領域在預測期內將以高複合年增長率增長。癌症患病率激增、產品快速上市以及研發活動增加等其他因素也推動了這一領域的增長。例如，2021 年 6 月，Nimble Therapeutics 宣布與 RayzeBio 合作，發現和開髮用於治療癌症的新型□類放射性藥物。

按分銷渠道，市場分為醫院藥店、零售藥店和在線藥店。預計在線藥店在預測期內將實現高複合年增長率。在線藥店的需求預計將受到互聯網使用量增加、遠程醫療採用增加、技術採用增加、便利性和時間效率等因素的影響。還有知名的電子藥房玩家，他們提供的節省也有望在不久的將來支持細分市場的需求。

為了更好地了解□治療行業的市場採用情況，將市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、意大利、歐洲其他地區） )、亞太地區（中國、日本、印度、亞太地區其他地區），以及世界其他地區，基於他們的全球規模。根據 Globocan 2020 報告，預計 2020 年美國將有 2,281,658 例新癌症診斷和近 612,390 例死亡。除此之外，主要參與者的存在、製藥公司增加投資以及政府有利的監管政策也推動了該地區的市場增長。例如，2022 年 7 月，Peptilogics 獲得了美國 FDA 對 PLG0206 的快速通道指定，用於治療假體周圍關節感染（ PJI ）。

內容

第一章市場介紹

市場定義
主要目的
利益相關者
限制

第 2 章研究方法或假設

研究過程
調查方法
受訪者簡介

第三章市場總結

第 4 章執行摘要

第 5 章 COVID-19 對□治療市場的影響

第六章多□藥物市場收入，2020-2028F

第 7 章市場洞察：按藥物類型分類

品牌
通用的

第 8 章市場洞察：按管理途徑

靜脈注射
經粘膜
口語
透皮

第 9 章市場洞察：按應用

癌症
新陳代謝
心血管疾病
呼吸系統
血液病
傳染病的對策
皮膚科
中樞神經系統
其他

第 10 章市場洞察：按分銷渠道

醫院藥房
零售藥房
在線藥店

第 11 章市場洞察：按地區

北美
- 美國
- 加拿大
- 其他北美地區
歐洲
- 德國
- 英國
- 法國
- 意大利
- 西班牙
- 其他歐洲地區
亞太地區
- 中國
- 日本
- 印度
- 其他亞太地區
世界其他地區

第十二章□治療市場動態

市場驅動因素
市場挑戰

第十三章□治療市場機會

第14章多□藥物市場趨勢

第15章需求側與供給側分析

需求方分析
供應方分析

第16章價值鏈分析

第 17 章衝突場景

競爭格局
- 波特五力分析

第 18 章公司簡介

AbbVie Inc.
Pfizer Inc.
Lilly
Amgen Inc.
Bristol-Myers Squibb Company
Takeda Pharmaceutical Company Limited
Sanofi
F. Hoffmann-La Roche Ltd
GSK plc
Novartis AG

第十九章免責聲明

簡介目錄

Product Code: UMAU211767

Peptides are a combination of two or more amino acid monomers linked by amino acids. They act as efficient signaling molecules which bind to specific cell surface receptors, including ion channels and G protein-coupled receptors, and trigger intracellular effects. Researchers are actively utilizing peptides for the development of novel formulations indicated for the management of a wide range of acute and chronic diseases. . According to the American Cancer Society, "Cancer and Figures 2022", there was an estimated 1.9 million new cancer cases diagnosed in 2022. Moreover, as per the same source in 2020, the most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the U.S. Thus, the increasing cases of cancer require early treatment which is expected to increase the demand for peptide therapeutics over the forecast period.

The Peptide Therapeutics Market is expected to grow at a strong CAGR of 9% during the forecast period owing to the rising pharmaceutical investment for the development of novel drugs. For instance, in September 2021, Nimble Therapeutics collaborated with Incyte to discover novel peptide therapeutics. Further in July 2020, IRBM entered into a collaboration with Merck for the development of advanced peptide therapeutics. Such investments are expected to drive the market growth in the coming years

Based on drug type, the market is bifurcated into branded and generic. The branded category held a significant share of the market in 2021 mainly due to the rising research and development investment by pharmaceutical companies, product launches, and high prescription rates.

By route of administration, the market is segmented into parental, mucosal, oral, and transdermal. The parental category held a dominant share of the market in 2021. Several factors, such as high adoption rate, faster delivery of drugs, and ease of application are the major reasons for increasing their adoption in the global market. Currently, the majority of peptide therapeutics are delivered by parental route, which is also driving the market growth during the coming years.

On the basis of application, the market is segmented into cancer, metabolic, cardiovascular disorders, respiratory, hematological disorders, anti-infection, dermatology, CNS, and others. The cancer category is anticipated to grow with high CAGR during the forecast period owing to the high specificity and targetability of peptide therapeutics. Other factors, such as a surge in the prevalence of cancer, rapid product launches, and increasing research and development activities are also driving the segment growth. For instance, in June 2021, Nimble Therapeutics announced a collaboration with RayzeBio to discover and develop novel peptide-based radiopharmaceuticals for the treatment of cancer.

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies are expected to register a high CAGR during the forecast period. The demand for the online pharmacy segment is projected to be influenced by factors such as the rise in internet usage, rising telemedicine adoption, rising technology adoption, and convenience and time efficiency. Also, the availability of well-known e-pharmacy players and the savings they provide are expected to support segment demand in the near future.

For a better understanding of the market adoption of the peptide therapeutics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a dominant share in the market in 2021 owing to increased adoption of targeted therapy and rise in the incidence of cancer in U.S. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the U..S in 2020, with nearly 612,390 deaths. Apart from this, the presence of major key players, rising investments by pharmaceutical companies, and favorable government regulatory policies are also propelling the regional market growth. For instance, in July 2022, Peptilogics received U.S. FDA fast-track designation for PLG0206, for the treatment of periprosthetic joint infection (PJI).

Some of the major players operating in the market include: AbbVie Inc.; F. Hoffmann-La Roche Ltd; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Lilly; Sanofi; GSK plc; Novartis AG; and Takeda Pharmaceutical Company Limited.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Peptide Therapeutics Market
2.2. Research Methodology of the Peptide Therapeutics Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE PEPTIDE THERAPEUTICS MARKET

6 PEPTIDE THERAPEUTICS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DRUG TYPE

7.1. Branded
7.2. Generic

8 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

8.1. Parental
8.2. Mucosal
8.3. Oral
8.4. Transdermal

9 MARKET INSIGHTS BY APPLICATION

9.1. Cancer
9.2. Metabolic
9.3. Cardiovascular Disorder
9.4. Respiratory
9.5. Haematological Disorders
9.6. Anti-infection
9.7. Dermatology
9.8. CNS
9.9. Others

10 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online Pharmacies

11 MARKET INSIGHTS BY REGION

11.1. North America
- 11.1.1. U.S.
- 11.1.2. Canada
- 11.1.3. Rest of North America
11.2. Europe
- 11.2.1. Germany
- 11.2.2. U.K.
- 11.2.3. France
- 11.2.4. Italy
- 11.2.5. Spain
- 11.2.6. Rest of Europe
11.3. Asia-Pacific
- 11.3.1. China
- 11.3.2. Japan
- 11.3.3. India
- 11.3.4. Rest of Asia-Pacific
11.4. Rest of World